A Phase 2 interventional study of Metformin Hydrochloride and Placebo in Pelvic Pain and Endometriosis, sponsored by Boston Children's Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 15 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Boston Children's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.
Among the 152 studies in Pelvic Pain with a site in United States, this one is the 97th largest by planned enrollment of the 124 interventional ones that give a count, is one of 12 that started in 2025, is one of 22 in phase 2, reaches primary completion later than 11 of the 39 other live ones, and was the 130th registered.
377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.
Browse Pelvic Pain studies →37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 8–18
Oregon Health and Science University · Sites in United States
Ages 18–45 · Women only
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 15 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14 is below the median of 60 across 278 interventional studies indexed under Pelvic Pain.
Median enrollment 50 across the 124 interventional studies, 104 across the 28 observational. Of the 96 that completed or were terminated, 35 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 152 have an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 4 studies filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
16 of the studies in Pelvic Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06110065University of ArizonaCT-guided Pudendal Nerve Cryoneurolysis for Palliation of Malignancy-induced Pelvic Pain | 2026-11 |
| NCT05354869University of California, Los AngelesTransvaginal Electrical Stimulation for Myofascial Pelvic Pain | 2026-12 |
| NCT03794466University of Kansas Medical CenterQuantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization | 2026-12-31 |
| NCT06083597Weill Medical College of Cornell UniversityDevelopment of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain | 2026-12-31 |
| NCT06611501Boston Children's HospitalGlycemic Regulation as Endometriosis Adjunct Treatment | 2027-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 152 studies in Pelvic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot trial is to learn if a novel non-hormonal treatment, metformin hydrochloride, works to treat pelvic pain in young women with endometriosis. The main questions it aims to answer are:
Researchers will compare metformin to a placebo (a look-alike substance that contains no drug) to see if metformin works to treat pelvic pain.
Participants will:
Endometriosis is a chronic illness defined by the presence of endometrial glands and stroma outside the uterine lining. While prevalence estimates vary depending on the population studied, endometriosis is thought to affect approximately one in ten reproductive aged women, up to 50% of women with infertility, and up to 70% of adolescents with chronic pelvic pain. Over 10 million women in the United States have endometriosis and incur significantly higher direct and indirect healthcare costs than those without. Annual health care costs are estimated at $100 billion in the United States alone. While the majority of patients report the onset of endometriosis symptoms during adolescence, delays in diagnosis are common and range from 7 to 12 years. During these delays, women may suffer from debilitating symptoms interfering with school and social activities, and commonly experience reduced health-related quality of life and work productivity. When left untreated, endometriosis can progress significantly in over 50% of patients and result in a higher stage of disease. Therefore, timely intervention and maintenance of therapy is critical for preventing the progression of disease and patient burden.
Therapeutic options for endometriosis include surgical and medical management. Because surgery is not curative, long-term medical therapy is often advised to prevent recurrence of symptoms and retard the progression of disease. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for endometriosis-related pain but do not remove or decrease deposits of ectopic endometrium. Hormonal therapies are the mainstay of medical therapy as they can inhibit prostaglandin production that contributes to pain, and cause decidualization and atrophy of ectopic endometrial tissue. Unfortunately, hormonal treatments have varied degrees of success and no data support one treatment over another. Additionally, the treatment choice may be limited to medication side effects, availability, costs, and contraceptive needs. Hormonal treatments do not cure endometriosis; 11-19% of women may not experience any relief with medical therapy, and up to a third of women experience recurrence of pain symptoms after treatment cessation. Additionally, as endometriosis is predominantly a disease of young reproductive-aged women, patients may desire a treatment with a different mechanism of action that does not impact ovarian function and fertility. There remains an unmet clinical need among women with endometriosis for effective and well-tolerated medical therapies.
Metformin, an insulin-sensitizing oral biguanide, is approved for the treatment of type 2 diabetes. Several published studies using in vitro and animal models have implicated metformin with a regression of endometriotic implants and reduction of inflammatory activity. Yet, the mechanisms of action of metformin remain to be further elucidated. Only one prospective study to date has investigated the use of metformin in humans as monotherapy for endometriosis; this study had substantial limitations. Further investigation will be improved with participant and provider blinding, use of validated pain measures, and inclusion of a broader population of patients affected by endometriosis. A randomized clinical trial is necessary to investigate the mechanisms and efficacy of metformin as an anti-endometriotic drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo tablets orally daily for a total of 6 months of treatment.
Drug: Placebo
metformin hydrochloride 500 mg capsules daily for a total of 6 months of treatment
Drug: Metformin Hydrochloride
Metformin dosage titrated from 500 mg/daily for 2 weeks, then 1000 mg/daily for 2 weeks, 1500 mg/daily for 2 weeks, and then achieving 2000 mg/daily for a duration of 6 months of treatment.
1 tablet orally with evening meal for 2 weeks, then 1 tablet twice daily for 2 weeks, then 3 tablets split twice daily for 2 weeks, then 4 tablets split twice daily, for a total of 6 months of treatment.
Also known as: Placebo capsule
Change in pain assessed by the Brief Pain Inventory Interference Scale (BPI) over 6 months
The BPI Interference Scale is a 7-item composite pain measurement. This self-report measure assesses the extent to which pain interferes with various components of physical and emotional functioning and sleep. The items in this scale can be grouped into those that assess physical functioning (general activity; walking ability; normal work, including both work outside the home and housework), those that assess emotional functioning (mood; relations with people; enjoyment of life), and a single item that assess the extent to which pain interferes with sleep. The arithmetic mean of the seven interference items can be used as a measure of pain interference. The BPI is anchored between a scale of zero (no pain/interference) to ten (maximum pain/interference). The magnitude of treatment-associated change in BPI Interference Scale scores in open-label and randomized clinical trials ranges from 1 to 3 points, depending on the specific pain conditions and treatments studied.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Change in pain severity measured by Visual Analog Scale (VAS) over 6 months
VAS: A measurement of pain intensity, assessed by a 0 to 10 numerical rating scale, to rate maximum and average pain intensity over the preceding 7 days. Higher scores indicate more severe pain intensity.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Change in emotional functioning assessed by Beck Depression Inventory-II (BDI) over 6 months
The BDI is a 21-item self-report instrument that provides a rapid assessment of depressive symptoms. BDI has been used in many studies of chronic pain, including chronic pelvic pain and endometriosis. Total scores on the BDI range from 0 to 63. The BDI takes about 5-10 minutes to complete. Scores below 13 should be considered to reflect "minimal or no" depression, with score ranges of 14 to 19, 20 to 28, and 29 to 63 reflect "mild to moderate," "moderate to severe," and "severe" depression, respectively.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Change in ratings of overall improvement assessed by the Patient Global Impression of Change scale (PGIC)
The PGIC is a seven-point single-item scale with options ranging from 'very much worse' to 'very much improved'. There has been widespread use of the PGIC in recent endometriosis clinical trials, as it readily interprets a person's evaluation of the importance of their improvement or worsening.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Change in quality of life, measured via Endometriosis Health Profile-30 (EHP-30)
The EHP-30 is a reliable instrument and recommended by the American Society for Reproductive Medicine and the European Society for Human Reproduction and Embryology. The questionnaire includes 30 questions in five subcategories, with each category addressing specific problem areas of pain, control and powerlessness, emotional wellbeing, social support, and self-image.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in sexual satisfaction for participants who are sexually active measured by the New Sexual Satisfaction Scale
The NSSS is a 20-item measure assessing sexual sensations, sexual presence/awareness, sexual exchange, emotional connection/closeness, and sexual activity. The full scale takes 5 minutes to complete.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Complete health and medication history assessed by the World Endometriosis Research Foundation (WERF) questionnaire
Study participants will complete an expanded version of the WERF questionnaire for a complete health and medication history
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in serum angiogenic/inflammatory markers
Serum samples will also be obtained for measures of inflammation, to test the hypothesis that endometriosis-relevant inflammatory markers will decrease over time in patients treated with metformin compared to those receiving placebo. These markers will include IL-6, IL-8, and VEGF based on the results of prior studies in which metformin appeared to reduce these levels in humans with endometriosis and from endometriotic implants in rats. C-reactive protein (CRP) will also be assessed; CRP has been shown to be upregulated, especially when examined with a high sensitivity assay making it possible to detect subclinical inflammation in women with endometriosis.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in school and/or work attendance
School and/or work attendance will be assessed at each visit.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Change in pregnancy status
Urine pregnancy test throughout the study as current pregnancy is an exclusion criteria
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in serum lactate levels
Serum lactate will be measured at baseline and then possibly at three and six months, if needed.
Time frame: baseline, three and six months if needed
Changes in pain
Subjects will keep a daily symptom diary to track pain for 6 months.
Time frame: daily for 6 months
Incidence of vaginal bleeding over six months
Measurement of the incidence of vaginal bleeding using a daily symptom diary to document the presence/absence of vaginal bleeding
Time frame: daily for 6 months
Usage of any pain medications (both prescription and over the counter)
Usage of any pain medications (both prescription and over the counter) tracked in a daily symptom diary for 6 months
Time frame: daily for 6 months
Changes in height
Height, in cm, will be obtained at each study visit (at baseline, 3 months, and 6 months).
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in weight
Study subjects will have their weight obtained at each study visit given the potential impact on weight by metformin.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in serum insulin c-peptide level
Serum insulin c-peptide levels will be collected at baseline and again at 6-months given metformin impact on lowering c-peptide levels.
Time frame: at baseline and 6 months
Changes in hemoglobin and mean corpuscular volume
A Complete Blood Count (CBC) will be collected at baseline and again at 6-months due to the potential adverse effect of megaloblastic anemia by metformin, which would be detected by the hemoglobin and mean corpuscular volume.
Time frame: at baseline and 6 months
Changes in vitamin B12 levels
Serum vitamin B12 levels will be obtained at baseline and at 6 months due to the possible adverse effect of vitamin b12 deficiency by metformin
Time frame: at baseline and 6 months
Changes in lipid levels
A lipid panel will be collected at baseline and again at 6-months due to the potential lipid-lowering activity of metformin.
Time frame: at baseline and 6 months
Changes in hemoglobin A1c
At each study visit, (baseline, 3 months, and 6 months), HbA1c will be assessed serially given the glycemic impact and effect of reducing HbA1c by metformin.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in metabolic panel
At each study visit, (baseline, 3 months, and 6 months), a comprehensive metabolic panel will be assessed serially to monitor for any potential kidney impairment that might affect continuation of treatment or changes in electrolytes in the setting of gastrointestinal distress.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in temperature
A physical exam will be conducted at baseline, three months, and six months to obtain changes in temperature.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in heart rate
A physical exam will be conducted at baseline, three months, and six months to obtain changes in heart rate.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Changes in blood pressure
A physical exam will be conducted at baseline, three months, and six months to obtain changes in blood pressure.
Time frame: once at each of the three visits (at baseline, 3 months, 6 months)
Plan to share: No — IPD will not be shared so that patient privacy and confidentiality is maintained during this study.
Started May 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.
Of 14 phase 2 interventional studies under Pelvic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 29. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin